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COST-EFFECTIVENESS OF A LIFESTYLE INTERVENTION FOR
HYPERTENSION: AN OPEN RANDOMISED CONTROLLED
TRIAL
Martikainen JA1, Kastarinen M2, Puska P3, Nissinen A3
1University of Kuopio, Kuopio, Finland, 2Kuopio University Hospital,
Kuopio, Finland, 3National Public Health Institute, Helsinki, Finland
Elevated blood pressure (BP) is a common chronic condition.
Hypertension is a signiﬁcant risk factor for cardiovascular dis-
eases (CVD) and mortality. In addition, its consequences are a
signiﬁcant burden to society due to hospital admissions, use of
anti-hypertensive drugs, sickness leaves, and disability pensions.
OBJECTIVE: To estimate the cost-effectiveness of systematic
health counselling in the treatment of hypertension in primary
health care. METHODS: A cost-effectiveness analysis was per-
formed alongside an open clinical trial, where 698 subjects aged
25–74 years with systolic BP (SBP) 140–179 mmHg and/or dias-
tolic BP (DBP) 90–109 mmHg or antihypertensive drug treat-
ment were randomised to intervention and usual care groups.
The intervention was provided by trained public health nurses,
who gave lifestyle counselling targeting weight reduction, restric-
tion in salt, alcohol and saturated fat consumption, and increas-
ing leisure time physical activity. Short-term effects in the BP
levels were extrapolated to obtain 10-year fatal CVD events by
using the SCORE risk function. Incremental cost-effectiveness
(ICER) was determined as cost per 1 mmHg reduction in SBP
and DBP levels, and cost per life-years saved (LYS). Uncertainty
was handled using a parametric Bayesian framework. RESULTS:
The absolute change in the BP levels was signiﬁcantly greater in
the intervention group among patients without antihypertensive
drug treatment compared to similar patients in the usual care
group (−2.4 mmHg in SBP and −2.0 mmHg in DBP). The differ-
ence in the BP reduction in patients with antihypertensive drug
treatment was not signiﬁcant between groups. For the patients
not receiving antihypertensive drugs ICERs were €60 per 
1 mmHg reduction in SBP and €72 per 1 mmHg reduction in
DBP, and €98,000 per LYS. CONCLUSIONS: The lifestyle coun-
selling in the primary care setting is a moderately cost-effective
method to treat patients to the treatment goals at least for
patients without previous antihypertensive drug treatment.
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CLINICAL EFFECTIVENESS OF BETALOC ZOC COMPARED 
TO METOPROLOL TARTRATE OR CARVEDILOL IN
HYPERTENSION TREATMENT
Kawalec P1, Borek E2
1Jagiellonian University, Kraków, Poland, 2Astra Zeneca Poland,
Warsaw, Poland
OBJECTIVES: To assess the clinical effectiveness of Betaloc
ZOC (metoprolol succinate), metoprolol tartrate or carvedilol in
a treatment of primary arterial hypertension. METHODS: Sys-
tematic review of published clinical trials selected in accordance
with Cochrane Collaboration guidelines was conducted to assess
effectiveness and safety of the drugs in hypertension treatment.
Systematic review was conducted in August 2005; Medline
(Pubmed) Cochrane and EMBASE were searched to ﬁnd relevant
clinical trials. Only randomized clinical trials with credibility
assessment of two or more points according to Jadad scale were
included in the systematic review. In case no clinical trials with
“head to head comparison” between metoprolol succinate and
metoprolol tartrate or carvedilol were found, indirect effective-
ness assessment with a common reference was done. Clinical
data was pooled with RevMan 4.2. RESULTS: Six relevant clin-
ical trials with direct comparison of metoprolol succinate and
metoprolol tartrate were found. Pooled clinical data on proba-
bility of diastolic pressure normalization (BP < 95 mmHg) in case
of Betaloc ZOC use compared to metoprolol tartrate revealed
insigniﬁcant trend favouring Betaloc ZOC (respectively 69.2%
vs. 63.4%); no signiﬁcant difference in safety proﬁle was shown
between the drugs (respectively 40.7% vs. 41.9%). Systematic
review revealed no randomized, “head to head comparison” clin-
ical trials with metoprolol succinate and carvedilol; indirect com-
parison of the drugs with atenolol as a common reference was
done to assess their clinical effectiveness. Indirect comparison
showed superiority of Betaloc ZOC over carvedilol in hyperten-
sion treatment (respectively: 81% vs 71.4%); no signiﬁcant dif-
ferences in safety proﬁle were revealed. CONCLUSIONS:
Betaloc ZOC use in place of metoprolol tartrate or carvedilol
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OBJECTIVE: A recent meta-regression of clinical trials of statins
demonstrated a linear relationship between magnitude of reduc-
tion of low-density lipoprotein cholesterol (LDL-C) and magni-
tude of cardiovascular risk reduction. We hypothesized that
magnitude of reduction of LDL-C would be roughly propor-








patients who begin with low and high levels and regardless of
ﬁnal level achieved. METHODS: A cohort of 27,660 patients
with coronary artery disease, peripheral vascular disease, or dia-
betes mellitus were selected and followed retrospectively for their
ﬁrst myocardial infarction or revascularization recorded in 
the New England Veterans Affairs database. Pre-outcome 
low-density lipoprotein cholesterol reduction was categorized as
follows: <10 mg/dl, reference; 10–39 mg/dl, small reduction;
40–69 mg/dl, moderate reduction; >70 mg/dl, large reduction.
Cox proportional hazards was used to determine hazard ratios
for each category of lipid reduction compared to reference and
stratiﬁed by high or low initial LDL-C, adjusting for initial LDL-
C, statin use, age, gender, and co morbidities. RESULTS: Among
patients with initial LDL-C above the median of 133 mg/dL,
hazard ratios (95% conﬁdence intervals) for small, moderate,
and large reductions compared to reference were 0.90
(0.85–0.96), 0.84 (0.79–0.90), and 0.76 (0.70–0.83) respectively.
A total of 3448 or 24% of such patients achieved a ﬁnal level
<100 mg/dL. Among patients with initial levels below the
median, hazard ratios (95% conﬁdence intervals) for small, 
moderate, and large reductions were 0.90 (0.85–0.96), 0.87
(0.79–0.96), and 0.76 (0.56–1.05) respectively. A total of 5492
or 40% of such patients achieved ﬁnal level <100 mg/dL. CON-
CLUSION: These data suggest that magnitude of reduction in
low-density lipoprotein cholesterol is proportional to degree of
reduction in cardiovascular risk, and that this effect holds both
for patients with initially low or high lipid levels, regardless of
whether a ﬁnal LDL-C of <100 mg/dL was achieved.
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ASCOT-LIKE PATIENT PREVALENCE AMONG THE
HYPERTENSIVES IN SPAIN
Sicras A1, F Bobadilla J2, Moreno R3,Arístegui R2, García M4
1Badalona Servicios Asistenciales, Barcelona, Spain, 2Pﬁzer Spain,
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OBJECTIVES: The lipid-lowering arm of ASCOT demonstrated
that in hypertensive patients, in primary prevention who are not
conventionally deemed dyslipidaemic and with at least three car-
diovascular risk factors (CVRF), atorvastatin ten mg conferred
a reduction in CV morbimortality. There are no data regarding
the prevalence of these patients among the hypertensives in
Spain. The objective is to determine the prevalence of the patient
as deﬁned in the ASCOT among the Spanish hypertensives.
METHODS: Data from 2004 to 2005 of 6309 hypertensives
from Spanish primary care centres were studied. We analyzed the
following variables: left-ventricular hypertrophy, other speciﬁed
abnormalities on EKG, type 2 diabetes, peripheral arterial
disease, previous stroke, gender, age, microalbuminuria,
smoking, ratio total cholesterol/HDL-cholesterol, and premature
family history of CHD. We analyzed the Number of CVRF as
deﬁned in ASCOT and the percentage of patients with CVRF ≥3
(with normal TC and in primary prevention). RESULTS: Of the
6309 patients, 2528 (40%) had history of CHD and/or heart
failure and/or TC >250 mg/dl and/or a statin treatment. The
presence of ASCOT-CVFR ≥3 was analyzed in the 3781 remain-
ing ones. The percentage of additional CVRF relative to these
3781 patients was: 0 FRCV: 4.3%; 1 FRCV: 24.6%; 2 FRCV:
30.4%; 3 FRCV: 22.2%; 4 FRCV: 11.8%; 5FRCV: 5.1%; 6
FRCV: 1.3%; 7 FRCV: 0.3%; 8 FRCV: 0.03%. There were 1540
patients (40.7%) with CVRF ≥3. This percentage, in relation to
the whole population of hypertensives (6309) was 24.4%. CON-
CLUSIONS: Because of the retrospective nature of the design, it
is advisable to be prudent in the external generalization. Never-
theless a high prevalence (at least 40.7%) of the ASCOT-patient
(CVRF ≥3), relative to a population of Spanish hypertensive
patients in primary prevention, not treated with statins and with
total cholesterol ≤250 mg/dL, have been demonstrated.
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ANALYSIS OF PRESCRIBING PATTERNS OF
ANTIHYPERTENSIVE AGENTS (AA) BEFORE AND AFTER
PUBLICATION OF THE ANTIHYPERTENSIVE AND LIPID-
LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL
(ALLHAT)
Brixner D1, Maio V2
1The University of Utah College of Pharmacy, Salt Lake City, UT, USA,
2Thomas Jefferson University, Philadelphia, PA, USA
OBJECTIVE: The ALLHAT study, published in December of
2002, indicated improved outcomes for hypertensive patients on
thiazide diuretics. This study evaluated the utilization of thi-
azides in hypertensives in the year before and after the publica-
tion of these results in a national primary care database.
METHODS: A retrospective review of an electronic medical
record (EMR) database (GE Medical Systems Centricity) con-
taining the ambulatory health record data for over 3.2 million
individuals was conducted. Patients with an ICD-9 code for
hypertension (HPTN) and a GPI code for thiazide diuretic were
identiﬁed in calendar years 2002 and 2003. Patients in each year
on thiazides, on or after HPTN diagnosis, were taken as a per-
centage of those with hypertension. RESULTS: In the year 2002
there were 81,916 patients with hypertension, 40,392 patients
on thiazide diuretics and 17,520 patients with both. Of those,
15,253 had their thiazide prescription on or after the date of
HPTN diagnosis. In 2003 there were 114,347 patients with
HPTN, 56,796 on thiazides, 26,199 with HPTN and 22,321
with their thiazide prescription on or after HPTN diagnosis. The
percent of hypertensives on thiazides was 18.62% in 2002 and
19.52% in 2003 with an increase of 0.9% in thiazide use in
patients with hypertension. CONCLUSION: Despite published
evidence of improved outcomes for hypertensive patients treated
with thiazide diuretics, the increase utilization in a primary care
database was modest.
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MAIN CARDIOVASCULAR RISK FACTORS: ASSOCIATION AND
CONTROL IN A PRIMARY HEALTH CARE SETTING
Sicras A1, Navarro R1, Rejas J2, F Bobadilla J2, García M3, González P2
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OBJECTIVES: To determine the association and The rapeutic
control goals of certain cardiovascular risk factors (CVRF) in a
Spanish primary care population. METHODS: A retrospective
study was performed based on patient’s data from ﬁve ambula-
tory primary care centres. Patients aged >18 years, attended
during year 2004, with at least one major CVRF were included.
The following variables were analysed: age, sex, main diagnosis
(hypertension, dyslipidemia, diabetes and/or cardiovascular
event [ECV]) and clinical parameters (systolic blood pressure,
diastolic blood pressure, LDLc, HbA1c). Therapeutic control
goals were established according to NCEP-ATP III. A bivariant
analysis and a binary logistic regression model were performed
to ﬁt the model. The statistical program SPSS was used with a
5% signiﬁcance level. RESULTS: A total of 15,470 patients had
at least one CVRF. Mean age was 61.3 ± 14.3; 53.7% were
female and 14.2% had a history of CVD. The diagnosis was
hypertension in 60.6%, diabetes in 26.7% and hipercoles-
terolemia in 49.5%. The presence of CVRF >3 was conﬁrmed in
5.8% and CVD in 28.3%. The percentage of patients who
